Koretz R L
Gut. 1986 Nov;27 Suppl 1(Suppl 1):85-95. doi: 10.1136/gut.27.suppl_1.85.
Although malnutrition is associated with poor clinical outcome, it cannot be inferred that better nutrition will improve clinical outcome. Efficacy of a proposed regimen is best established by prospective, randomised, controlled trials. Cost effectiveness is only an issue if efficacy exists. Patients with long term temporary, or permanent, inadequate bowel syndrome are candidates for parenteral nutrition. Most of the prospective, randomised, controlled trials testing the value of nutritional support in other diseases, however, have failed to show that this treatment has a beneficial clinical effect. Areas where these trials have shown a possible clinical benefit include the perioperative care of patients with upper gastrointestinal cancer, elemental diet treatment of Crohn's disease, and branched chain amino acid infusions in hepatic encephalopathy. Even in these instances, it is not clear that such treatment will prove to be cost effective (compared with other currently available treatments).
尽管营养不良与临床预后不良相关,但不能就此推断营养状况改善就能提升临床预后。一种提议疗法的疗效最好通过前瞻性、随机、对照试验来确定。只有在存在疗效的情况下,成本效益才成为一个问题。患有长期临时性或永久性肠功能不全综合征的患者是肠外营养的适用对象。然而,大多数检验营养支持对其他疾病价值的前瞻性、随机、对照试验均未能表明这种治疗具有有益的临床效果。这些试验显示可能具有临床益处的领域包括上消化道癌患者的围手术期护理、克罗恩病的要素饮食治疗以及肝性脑病的支链氨基酸输注。即便在这些情况下,也不清楚这种治疗是否会被证明具有成本效益(与其他现有治疗方法相比)。